Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis
Infectious Disease: COVID-19

This page shows you your search results in order of date.

Order by Relevance | Date

Total 34 results found since Jan 2013.

Risk of thromboembolic events in non-hospitalized COVID-19 patients: A systematic review
Eur J Pharmacol. 2023 Jan 11:175501. doi: 10.1016/j.ejphar.2023.175501. Online ahead of print.ABSTRACTThe risk of thromboembolism in non-hospitalized COVID-19 patients remains uncertain and was assessed in this review to better weigh benefits vs. risks of prophylactic anticoagulation in this population. A search was performed through three databases: Medline, Embase, and Cochrane Library until 2022. Self-controlled case series, case-control and cohort studies were included, and findings summarized narratively. Meta-analyses for risk of thromboembolism including deep vein thrombosis (DVT), pulmonary embolism (PE), and myoca...
Source: European Journal of Pharmacology - January 14, 2023 Category: Drugs & Pharmacology Authors: Gaelle P Massoud Dana H Hazimeh Ghadir Amin Wissam Mekary Joanne Khabsa Tarek Araji Souha Fares Mathias Mericskay George W Booz Fouad A Zouein Source Type: research

Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19
CONCLUSION AND RELEVANCE: Approximately 52% of patients on warfarin were eligible for DOACs. This presents an opportunity to reduce patient exposure to health care settings and health care utilization in the setting of COVID-19. Increased costs of DOACs need to be assessed.PMID:36373362 | PMC:PMC9663271 | DOI:10.1177/10600280221136874
Source: The Annals of Pharmacotherapy - November 14, 2022 Category: Drugs & Pharmacology Authors: Rachel Hess Elizabeth Renner Erin Mouland Denise Sutter-Long Nghi Ha Source Type: research

Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective
Curr Vasc Pharmacol. 2022;20(4):333-340. doi: 10.2174/1570161120666220428101337.ABSTRACTThe neurological complications of Coronavirus 2019 (COVID-19) including stroke have been documented in the recent literature. COVID-19-related inflammation is suggested to contribute to both a hypercoagulable state and haemorrhagic transformation, including in younger individuals. COVID-19 is associated with a heightened risk of ischaemic stroke. Haemorrhagic stroke in COVID-19 patients is associated with increased morbidity and mortality. Cerebral venous sinus thrombosis (CVST) accounts for <1% of stroke cases in the general populat...
Source: Current Vascular Pharmacology - November 3, 2022 Category: Drugs & Pharmacology Authors: Alan King Karen M Doyle Source Type: research